https://www.thebodypro.com/category/switching-stopping-hiv-treatment-pro
HIV Treatment Strategies

Switching or Stopping HIV Treatment

The Latest

slacklining
News

This Week in HIV Research: So Many Relative Risks

July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.

By Barbara Jungwirth and Myles Helfand
Newton's Cradle
News

When People Stop Newer HIV Meds, Time to Viral Rebound Not Better Than With Older Antiretroviral Therapy, NIH Study Finds

Researchers are trying to understand treatment interruptions as part of work to develop a future HIV cure and therapies that will not involve medications.

By Martha Kempner
selective focus image of Gilead Truvada for PrEP
News

This Week in HIV Research: PrEP So White

May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.

By Barbara Jungwirth and Myles Helfand
droplet of blood
News

This Week in HIV Research: How Dangerous Is Low-Level Viremia?

May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.

By Barbara Jungwirth and Myles Helfand
pill bottles and cash
Conference Coverage

A PrEP Pricing Pickle: Descovy Will Need a Drastic Discount to Be Worthwhile, Study Finds

With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.

By Myles Helfand
men on beach
News

This Week in HIV Research: Do You Believe in U=U?

Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.

By Barbara Jungwirth and Myles Helfand
Two-Drug TANGO photo illo
Features

TANGO, the Most Relevant Two-Drug Antiretroviral Therapy Trial of the Year

Whether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary?

By David Alain Wohl, M.D.
Several Medication Pill Bottles On Table In Front Of Windows
Conference Coverage

Patients With HIV Should Think About How Many Pills They Take a Day

Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.

By Mathew Rodriguez
Timothy Ray Brown at the Association of Nurses in AIDS Care (ANAC) in Portland, Oregon
News

The Berlin Patient, the First Person Ever Cured of HIV, on Taking PrEP: "I Want a Full Sexual Life"

Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.

By Sony Salzman
human skeleton posed in thinking position
News

This Week in HIV Research: If I Could Turn Back Ossein

Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.

By Barbara Jungwirth and Myles Helfand